Obstructive sleep apnea (OSA) is a highly prevalent sleep-related breathing disorder affecting an estimated 1.36 billion people worldwide. It is associated with excessive daytime sleepiness, impaired quality of life, cardiovascular and cerebrovascular disease, and increased all-cause mortality, and is a substantial economic burden. Although positive airway pressure (PAP) remains the gold-standard therapy, its effectiveness is limited by suboptimal tolerance and adherence, leading to interest in pharmacological alternatives. Among emerging options, AD109, a combination of the selective noradrenergic reuptake inhibitor atomoxetine (75 mg) and the antimuscarinic aroxybutynin (2.5 mg), taken once daily, represents a mechanistically targeted approach that acts on the neuromuscular roots of OSA. Preclinical work demonstrated that pharyngeal dilator tone is suppressed in sleep through withdrawal of noradrenergic excitation and active muscarinic inhibition at the hypoglossal motor nucleus, providing the rationale for combining a noradrenergic agent with an antimuscarinic to augment hypoglossal motor output and preserve upper-airway patency. Building on a series of smaller precursor trials of noradrenergic–antimuscarinic combinations, AD109 has demonstrated consistent efficacy across phase 2 and two large phase 3 trials (SynAIRgy and LunAIRo), with meaningful reductions in the apnea–hypopnea index, improvements in nocturnal oxygenation, and a generally favorable tolerability profile. These findings position AD109 as a promising oral option, particularly for adults with mild to severe OSA who cannot tolerate or decline PAP. However, its effect on long-term cardiovascular, neurocognitive, and mortality outcomes remains to be established. This commentary reviews the mechanism of action and clinical trial evidence for AD109 and related combinations.
